25.51  -1.15 (-4.31%)		08-21 16:00
Open: 26.41 High: 28.4731 Volume: 20,801		Pre. Close: 26.66 Low: 25 Market Cap: 89(M)

Short term
Mid term
Targets	6-month :	32.64	1-year :	34.77
Resists	First :	27.95	Second :	29.77
Pivot price	27.52
Supports	First :	25	Second :	20.8
MAs	MA(5) :	26	MA(20) :	27.44
	MA(100) :	26.12	MA(250) :	26.64
MACD	MACD :	-0.3	Signal :	0
%K %D	K(14,3) :	12.5	D(3) :	10.2
RSI	RSI(14): 42.9
52-week	High :	37.5	Low :	18.19

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ PTHS ] has closed above bottom band by 11.9%. Bollinger Bands are 30.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	28.54 - 28.68	28.68 - 28.79
Low:	24.65 - 24.82	24.82 - 24.96
Close:	25.27 - 25.53	25.53 - 25.74

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

Tue, 18 Aug 2026
Pelthos Therapeutics Inc. SEC Filing (Aug 18, 2026) - Stock Titan

Thu, 13 Aug 2026
Pelthos Therapeutics Reports 45% Quarter-Over-Quarter Zelsuvmi Net Product Revenue Growth to $15.4 Million in Second Quarter 2026 - Quiver Quantitative

Thu, 13 Aug 2026
Pelthos Therapeutics Inc. 2026: Revenue $15.6M, Net income ($23.42M), EPS ($6.62) — 10-Q Summary - TradingView

Thu, 13 Aug 2026
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Wed, 12 Aug 2026
Earnings To Watch: Pelthos Therapeutics Inc (PTHS) Reports Q2 20 - GuruFocus

Tue, 04 Aug 2026
Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.